Literature DB >> 17305481

Small molecule inhibitors of Stat3 signaling pathway.

Jinxia Deng1, Fedora Grande, Nouri Neamati.   

Abstract

Constitutive activation of the Signal Transducers and Activators of Transcription 3 (Stat3) meditated signaling pathway is very important for cell growth and survival. Compelling evidence from mechanistic studies with antisense, RNA interference (RNAi), peptides, and small molecular inhibitors indicate that blocking Stat3 signaling can lead to successful suppression of tumor cell growth and apoptosis. Thus, Stat3 is an attractive molecular target for the development of novel cancer therapeutics. In this article, we present the first comprehensive review focusing on small molecule inhibitors that effectively block the Stat3 signaling pathway. These inhibitors, from a structural point of view, are divided into five classes of compounds. They include (1) natural products and derivatives, such as curcumin, resveratrol and others, (2) tyrphostins, (3) platinum-containing complexes, (4) peptidomimetics, and (5) azaspiranes. Some compounds may have multiple targets including Stat3 protein, therefore these compounds need further optimization and validation. The purpose of this review is to provide a resource for researchers interested in Stat3 targeted small molecules which will be beneficial for database development and template design for future drug development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305481     DOI: 10.2174/156800907780006922

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  47 in total

1.  Mitogen-activated protein kinase signaling controls basal and oncostatin M-mediated JUNB gene expression.

Authors:  Mellissa J Hicks; Qiuping Hu; Erin Macrae; James DeWille
Journal:  Mol Cell Biochem       Date:  2015-02-08       Impact factor: 3.396

2.  A small-molecule compound identified through a cell-based screening inhibits JAK/STAT pathway signaling in human cancer cells.

Authors:  Byung Hak Kim; Chang-Hong Yin; Qianxu Guo; Erika A Bach; Haeryun Lee; Claudio Sandoval; Somasundaram Jayabose; Agnieszka Ulaczyk-Lesanko; Dennis G Hall; Gyeong-Hun Baeg
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

3.  Retinoic acid amide inhibits JAK/STAT pathway in lung cancer which leads to apoptosis.

Authors:  Hong-Xing Li; Wei Zhao; Yan Shi; Ya-Na Li; Lian-Shuang Zhang; Hong-Qin Zhang; Dong Wang
Journal:  Tumour Biol       Date:  2015-06-06

4.  Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.

Authors:  Jianyong Chen; Longchuan Bai; Denzil Bernard; Zaneta Nikolovska-Coleska; Cindy Gomez; Jian Zhang; Han Yi; Shaomeng Wang
Journal:  ACS Med Chem Lett       Date:  2010-05-13       Impact factor: 4.345

5.  An SH2 domain model of STAT5 in complex with phospho-peptides define "STAT5 Binding Signatures".

Authors:  Eleonora Gianti; Randy J Zauhar
Journal:  J Comput Aided Mol Des       Date:  2015-03-10       Impact factor: 3.686

6.  Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents.

Authors:  Haijun Chen; Zhengduo Yang; Chunyong Ding; Lili Chu; Yusong Zhang; Kristin Terry; Huiling Liu; Qiang Shen; Jia Zhou
Journal:  ACS Med Chem Lett       Date:  2013-01-15       Impact factor: 4.345

Review 7.  STAT3 regulation of glioblastoma pathogenesis.

Authors:  Núria de la Iglesia; Sidharth V Puram; Azad Bonni
Journal:  Curr Mol Med       Date:  2009-06       Impact factor: 2.222

8.  Inhibition of two gastric cancer cell lines induced by fucoxanthin involves downregulation of Mcl-1 and STAT3.

Authors:  Rui-Xue Yu; Rui-Tao Yu; Zhong Liu
Journal:  Hum Cell       Date:  2017-11-06       Impact factor: 4.174

9.  Characterization of STAT3 activation and expression in canine and human osteosarcoma.

Authors:  Stacey L Fossey; Albert T Liao; Jennifer K McCleese; Misty D Bear; Jiayuh Lin; Pui-Kai Li; William C Kisseberth; Cheryl A London
Journal:  BMC Cancer       Date:  2009-03-10       Impact factor: 4.430

10.  Alternative implication of CXCR4 in JAK2/STAT3 activation in small cell lung cancer.

Authors:  M Pfeiffer; T N Hartmann; M Leick; J Catusse; A Schmitt-Graeff; M Burger
Journal:  Br J Cancer       Date:  2009-05-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.